KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Interest & Investment Income (2016 - 2026)

Pacira BioSciences has reported Interest & Investment Income over the past 17 years, most recently at $1.9 million for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 72.01% year-over-year to $1.9 million; the TTM value through Mar 2026 reached $17.8 million, down 21.67%, while the annual FY2025 figure was $22.7 million, 15.46% up from the prior year.
  • Interest & Investment Income for Q1 2026 was $1.9 million at Pacira BioSciences, down from $2.3 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $8.5 million in Q3 2025 and troughed at $252000.0 in Q2 2022.
  • A 5-year average of $3.5 million and a median of $3.1 million in 2023 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: soared 3381.25% in 2022 and later plummeted 72.01% in 2026.
  • Year by year, Interest & Investment Income stood at $2.8 million in 2022, then rose by 22.98% to $3.4 million in 2023, then soared by 62.19% to $5.6 million in 2024, then crashed by 58.69% to $2.3 million in 2025, then fell by 15.9% to $1.9 million in 2026.
  • Business Quant data shows Interest & Investment Income for PCRX at $1.9 million in Q1 2026, $2.3 million in Q4 2025, and $8.5 million in Q3 2025.